Molecular evidence for the same clonal origin of multifocal papillary thyroid carcinomas

Clinical Cancer Research

Volumn 12, Issue 8, 2006, Pages 2414-2418

  McCarthy, Ryan P ^a   Wang, Mingsheng ^a   Jones, Timothy D ^a   Strate, Randall W ^a   Cheng, Liang ^a,b  

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FORMALDEHYDE; GENOMIC DNA; MICROSATELLITE DNA; PARAFFIN;

ARTICLE; CHROMOSOME 18P; CHROMOSOME 3P; CHROMOSOME 9P; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; CLONAL VARIATION; CONTROLLED STUDY; FEMALE; GENE LOSS; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; LASER CAPTURE MICRODISSECTION; MICROSATELLITE MARKER; MOLECULAR PHYLOGENY; PAPILLARY CARCINOMA; PAPILLOMA; PRIORITY JOURNAL; THYROID CARCINOMA; THYROIDECTOMY; TUMOR SUPPRESSOR GENE; X CHROMOSOME INACTIVATION;

ADULT; AGED; CARCINOMA, PAPILLARY; CHROMOSOMES, HUMAN, PAIR 18; CHROMOSOMES, HUMAN, PAIR 3; CHROMOSOMES, HUMAN, PAIR 9; CLONE CELLS; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS; MIDDLE AGED; THYROID NEOPLASMS; THYROIDECTOMY; X CHROMOSOME INACTIVATION;

EID: 33646399142     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2818     Document Type: Article

References (38)

1. Sherman SI. Thyroid carcinoma. Lancet 2003;361:501-11.
2. Grebe SK, Hay ID. Follicular cell-derived thyroid carcinomas. Cancer Treat Res 1997;89:91-140.
3. Katoh R, Sasaki J, Kurihara H, Suzuki K, Iida Y, Kawaoi A. Multiple thyroid involvement (intraglandular metastasis) in papillary thyroid carcinoma. A clinicopathologic study of 105 consecutive patients. Cancer 1992;70:1585-90.
4. Hedinger C, Williams ED, Sobin LH. The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer 1989;63:908-11.
5. Ringel MD, Ladenson PW. Controversies in the follow-up and management of well-differentiated thyroid cancer. Endocr Relat Cancer 2004;11:97-116.
6. Califano JA, Johns MM III, Westra WH, et al. An allelotype of papillary thyroid cancer. Int J Cancer 1996;69:442-4.
7. Gillespie JW, Nasir A, Kaiser HE. Loss of heterozygosity in papillary and follicular thyroid carcinoma: a mini review. In Vivo 2000;14:139-40.
8. Ward LS, Brenta G, Medvedovic M, Fagin JA. Studies of allelic loss in thyroid tumors reveal major differences in chromosomal instability between papillary and follicular carcinomas. J Clin Endocrinol Metab 1998;83:525-30.
9. Bongarzone I, Butti MG, Coronelli S, et al. Frequent activation of ret protooncogene by fusion with a new activating gene in papillary thyroid carcinomas. Cancer Res 1994;54:2979-85.
10. Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003;95:625-7.
11. Fagin JA. Challenging dogma in thyroid cancer molecular genetics - role of RET/PTC and BRAF in tumor initiation. J Clin Endocrinol Metab 2004;89:4264-6.
12. Fukushima T, Suzuki S, Mashiko M, et al. BRAF mutations in papillary carcinomas of the thyroid. Oncogene 2003;22:6455-7.
13. Grieco M, Santoro M, Berlingieri MT, et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990;60:557-63.
14. Hara H, Fulton N, Yashiro T, Ito K, DeGroot LJ, Kaplan EL. N-ras mutation: an independent prognostic factor for aggressiveness of papillary thyroid carcinoma. Surgery 1994;116:1010-6.
15. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003;63:1454-7.
16. Minoletti F, Butti MG, Coronelli S, et al. The two genes generating RET/PTC3 are localized in chromosomal band 10q11.2. Genes Chromosomes Cancer 1994;11:51-7.
17. Pierotti MA, Bongarzone I, Borrello MG, et al. Rearrangements of TRK proto-oncogene in papillary thyroid carcinomas. J Endocrinol Invest 1995;18:130-3.
18. Sozzi G, Bongarzone I, Miozzo M, et al. A t(10;17) translocation creates the RET/PTC2 chimeric transforming sequence in papillary thyroid carcinoma. Genes Chromosomes Cancer 1994;9:244-50.
19. Brandli DW, Ulbright TM, Foster RS, et al. Stroma adjacent to metastatic mature teratoma after chemotherapy for testicular germ cell tumors is derived from the same progenitor cells as the teratoma. Cancer Res 2003;63:6063-8.
20. Cheng L, MacLennan GT, Zhang S, Wang M, Pan CX, Koch MO. Laser capture microdissection analysis reveals frequent allelic losses in papillary urothelial neoplasm of low malignant potential of the urinary bladder. Cancer 2004;101:183-8.
21. Kernek KM, Ulbright TM, Zhang S, et al. Identical allelic losses in mature teratoma and other histologic components of malignant mixed germ cell tumors of the testis. Am J Pathol 2003;163:2477-84.
22. McCarthy RP, Zhang S, Bostwick DG, et al. Molecular genetic evidence for different clonal origins of epithelial and stromal components of phyllodes tumor of the prostate. Am J Pathol 2004;165:1395-400.
23. Kitamura Y, Shimizu K, Tanaka S, Ito K, Emi M. Association of allelic loss on 1q, 4p, 7q, 9p, 9q, and 16q with postoperative death in papillary thyroid carcinoma. Clin Cancer Res 2000;6:1819-25.
24. Rodrigues-Serpa A, Catarino A, Soares J. Loss of heterozygosity in follicular and papillary thyroid carcinomas. Cancer Genet Cytogenet 2003;141:26-31.
25. Cheng L, Gu J, Eble JN, et al. Molecular genetic evidence for different clonal origin of components of human renal angiomyolipomas. Am J Surg Pathol 2001;25:1231-6.
26. Cheng L, Gu J, Ulbright TM, et al. Precise microdissection of human bladder carcinomas reveals divergent tumor subclones in the same tumor. Cancer 2002;94:104-10.
27. Cheng L, Shan A, Cheville JC, Qian J, Bostwick DG. Atypical adenomatous hyperplasia of the prostate: a premalignant lesion? Cancer Res 1998;58:389-91.
28. Cheng L, Song SY, Pretlow TG, et al. Evidence of independent origin of multiple tumors from patients with prostate cancer. J Natl Cancer Inst 1998;90:233-7.
29. Gu J, Roth LM, Younger C, et al. Molecular evidence for the independent origin of extra-ovarian papillary serous tumors of low malignant potential. J Natl Cancer Inst 2001;93:1147-52.
30. Cheng L, Jones TD, McCarthy RP, et al. Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma. Am J Pathol 2005;166:1533-9.
31. Carcangiu ML, Zampi G, Rosai J. Papillary thyroid carcinoma: a study of its many morphologic expressions and clinical correlates. Pathol Annu 1985;20 Pt 1:1-44.
32. Iida F, Yonekura M, Miyakawa M. Study of intraglandular dissemination of thyroid cancer. Cancer 1969;24:764-71.
33. Russell WO, Ibanez ML, Clark RL, White EC. Thyroid carcinoma. Classification, intraglandular dissemination, and clinicopathological study based upon whole organ sections of 80 glands. Cancer 1963;16:1425-60.
34. Shattuck TM, Westra WH, Ladenson PW, Arnold A. Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. N Engl J Med 2005;352:2406-12.
35. Fernandes JK, Day TA, Richardson MS, Sharma AK. Overview of the management of differentiated thyroid cancer. Curr Treat Options Oncol 2005;6:47-57.
36. Haigh PI, Urbach DR, Rotstein LE. Extent of thyroidectomy is not a major determinant of survival in low- or high-risk papillary thyroid cancer. Ann Surg Oncol 2005;12:81-9.
37. Hay ID, Grant CS, Taylor WF, McConahey WM. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 1987;102:1088-95.
38. Jovanovic L, Delahunt B, McIver B, Eberhardt NL, Grebe SK. Thyroid gland clonality revisited: the embryonal patch size of the normal human thyroid gland is very large, suggesting X-chromosome inactivation tumor clonality studies of thyroid tumors have to be interpreted with caution. J Clin Endocrinol Metab 2003;88:3284-91.